TVTX Projected Dividend Yield
Travere Therapeutics Inc ( NASDAQ : TVTX )Travere Therapeutics is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with kidney, liver, and metabolic diseases. Co.'s approved products include: Thiola and Thiola EC (tiopronin), which are approved for the treatment of cystinuria, a genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones; and Cholbam (cholic acid capsules), which is approved for the treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder. 20 YEAR PERFORMANCE RESULTS |
TVTX Dividend History Detail TVTX Dividend News TVTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |